Overview

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the antitumor effect and safety of fludarabine phosphate tablet in combination with rituximab in patient with indolent lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine